放射性亚型预测I期肺腺癌的生存率和化疗效益:一项多中心研究
Guangyu Tao1, Dongying Wang2,3, Xin Cheng4
1Department of Radiology, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Insights into imaging
|March 2, 2026
概括
这项研究在I期肺腺癌 (LUAD) 患者中确定了基于CT的三种放射性亚型. 这些亚型预测了生存率,并识别了从辅助化疗中受益的高风险患者.
科学领域:
- 放射学和瘤学 放射学和瘤学
- 医学成像分析 医学成像分析
- 癌症亚型的分类
背景情况:
- 第一个阶段的肺腺癌 (LUAD) 存活率差异很大.
- 传统的分期缺乏全面的瘤异质性评估.
- 在LUAD中需要改进预后标记和个性化治疗策略.
研究的目的:
- 为I阶段的LUAD开发和验证基于CT的放射性亚型.
- 评估这些亚型与整体存活率 (OS) 的关联.
- 评估亚型预测辅助化疗效益和全身炎症状况的能力.
主要方法:
- 无监督的K-means集群应用到496名I阶段LUAD患者的1218个放射性特征.
- 使用来自两个中心的数据进行独立验证.
- 多变量考克斯回归和治疗-亚型相互作用分析用于预后价值和化疗效益预测.
主要成果:
- 三种不同的放射性亚型与OS的显著预后差异被确定.
- 一个高风险亚型 (集群2) 显示较差的OS (HR=15.71) 和炎症失衡.
- 亚型和辅助化疗之间的显著相互作用 (p<0.001),特别有利于高风险IB期患者.
结论:
- 基于CT的放射性亚型有效地分层了I阶段LUAD的预后.
- 已识别的高风险亚型与全身炎症相关.
- 放射性亚型预测了不同的辅助化疗效益,支持IB阶段的个性化治疗.
相关概念视频
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...